Company Overview - Shanghai Ruining Biotechnology Co., Ltd. completed nearly 100 million RMB in Series C financing, led by Fudan Science and Technology and Qiming Venture Partners, with Haoyue Capital as the exclusive financial advisor. The funds will be used for clinical advancement and commercialization of core products [2] - The company was established in 2018 and is headquartered in Shanghai, focusing on medical hydrogel technology platforms for innovative medical devices in major clinical scenarios such as tumor treatment [5] Products and Technology - The main products include: - Respacio® absorbable isolation hydrogel for tumor radiotherapy protection, which has completed domestic clinical trials and is included in the National Medical Products Administration's special review procedure for innovative medical devices. It has received breakthrough medical device designation from the FDA and has submitted an application for CE certification in Europe [5] - Tumor embolization hydrogel for the treatment of hypervascular malignant tumors, which is also included in the special review procedure [7] - Uterine adhesion prevention hydrogel, currently in the clinical enrollment stage [7] - The medical hydrogel technology platform is applicable in areas such as tumor radiotherapy protection, tumor interventional embolization, uterine adhesion prevention, tissue filling, tissue regeneration, and drug delivery [8] Financing History - The financing history of the company includes: - Series C on February 28, 2025, raising approximately 100 million RMB, led by Qiming Venture Partners and Fudan Science and Technology [10] - Series B on January 24, 2024, also raising approximately 100 million RMB [10] - Series A on September 23, 2022, and earlier rounds including angel investments [10] Patent Information - The company has several patents, including: - A rapid-dissolving hydrogel reagent kit, authorized on August 22, 2023 [11] - A chitosan-polyethylene glycol-lithium diatomite composite hydrogel, published on August 8, 2024 [11] - A drug-loaded embolization microsphere, authorized on December 28, 2022 [11]

Core Viewpoint - The article highlights the advancements in the medical technology sector, particularly focusing on innovative medical devices that have received special review status from the NMPA, indicating a growing trend in the industry towards innovation and regulatory support [1]. Company Summaries - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a leading global medical device supplier, established in 1991, with a revenue of 36.73 billion yuan in 2024, reflecting a 5.1% year-on-year growth, and a net profit of 11.67 billion yuan, up 0.7% [5]. - Wuxi Reiming Vision Technology Co., Ltd. specializes in the research and production of artificial lenses, having developed advanced hydrophobic acrylic materials and received CE certification for its products, indicating its strong R&D capabilities [6]. - Shenzhen Gamma Knife Technology Co., Ltd. has been focused on high-end medical equipment, particularly in radiation therapy, since its establishment in 1993, showcasing its commitment to innovation in the medical technology field [7]. - Suzhou Puno Medical Technology Co., Ltd. is a national high-tech enterprise founded in 2020, dedicated to the development of products related to tumor brachytherapy, emphasizing its strong R&D capabilities and innovative approach [10]. - Hangzhou Aijinglun Technology Co., Ltd. is an innovative ophthalmic medical device company established in 2015, known for its unique suspension-type intraocular lens, which fills a gap in the market for high-degree correction lenses [13]. - Beijing Shanning Kezhi Medical Device Co., Ltd. focuses on biodegradable zinc alloy technology, with products entering clinical trials, showcasing its innovative approach in the biomedical field [15]. - Medtronic, a global leader in medical technology founded in 1949, operates in over 70 disease areas, providing lifelong treatment solutions for chronic disease patients [18]. - Shanghai Yangshan Biotechnology Co., Ltd. was established in 2023, collaborating with top hospitals and dental clinics, indicating its strong market positioning in the dental sector [19]. - Xiamen Shide Medical Equipment Co., Ltd. emphasizes innovation in surgical instruments, having obtained numerous patents and certifications, and is recognized for its diverse product line [20][21]. - Guangzhou Xinhanglu Medical Technology Co., Ltd. focuses on innovative cardiac electrophysiology products, with a unique four-dimensional mapping system that enhances treatment precision [22]. - Shanghai Jinkui Medical Device Co., Ltd. specializes in cardiovascular interventional materials, having developed several pioneering products and maintaining strong R&D partnerships [23]. - Guokexin Medical Technology Co., Ltd. is engaged in the development of advanced medical equipment for boron neutron capture therapy, marking a significant advancement in cancer treatment technology [24]. - Shanghai Ruining Biotechnology Co., Ltd. focuses on high-end biomedical materials, with a strong emphasis on innovation and collaboration with leading cancer treatment centers [25]. - Suzhou Sainasi Medical Technology Co., Ltd. is dedicated to cardiac electrophysiology, providing innovative solutions and a comprehensive product line for the medical field [26].